US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NYSE
Annovis Bio Inc (ANVS)
Annovis Bio Inc (ANVS) ニュース

ANVS

Annovis Bio (ANVS)

Annovis Bio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ANVS

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/14	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
2024/05/13	20 : 30	GlobeNewswire Inc.	Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results	NYSE:ANVS	Annovis Bio Inc
2024/05/11	06 : 11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ANVS	Annovis Bio Inc
2024/05/10	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
2024/05/09	20 : 30	GlobeNewswire Inc.	Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease	NYSE:ANVS	Annovis Bio Inc
2024/05/07	06 : 12	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NYSE:ANVS	Annovis Bio Inc
2024/05/07	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
2024/05/06	20 : 30	GlobeNewswire Inc.	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders	NYSE:ANVS	Annovis Bio Inc
2024/04/29	23 : 10	GlobeNewswire Inc.	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease	NYSE:ANVS	Annovis Bio Inc
2024/04/02	20 : 30	GlobeNewswire Inc.	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	NYSE:ANVS	Annovis Bio Inc
2024/02/28	21 : 08	IH Market News	US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters…	NYSE:ANVS	Annovis Bio Inc
2024/02/13	04 : 00	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NYSE:ANVS	Annovis Bio Inc
2024/02/02	06 : 05	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NYSE:ANVS	Annovis Bio Inc
2023/11/23	06 : 27	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
2023/11/23	06 : 24	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
2023/11/23	06 : 21	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
2023/11/23	06 : 14	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NYSE:ANVS	Annovis Bio Inc
2023/11/22	04 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
2023/11/22	04 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
2023/11/22	04 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
2023/11/22	04 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ANVS	Annovis Bio Inc
2023/11/09	06 : 45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ANVS	Annovis Bio Inc
2023/11/02	20 : 30	Business Wire	Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients	NYSE:ANVS	Annovis Bio Inc
2023/11/02	01 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
2023/11/02	01 : 24	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ANVS	Annovis Bio Inc
2023/10/31	21 : 00	Business Wire	Annovis Bio Announces Pricing of $7.5 Million Public Offering	NYSE:ANVS	Annovis Bio Inc
2023/10/31	06 : 27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:ANVS	Annovis Bio Inc
2023/10/31	06 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ANVS	Annovis Bio Inc
2023/10/31	05 : 48	Business Wire	Annovis Bio Announces Launch of Proposed Public Offering	NYSE:ANVS	Annovis Bio Inc
2023/10/31	05 : 42	Business Wire	Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)	NYSE:ANVS	Annovis Bio Inc

Showing the most relevant articles for your search:NYSE:ANVS

1 2 3 4 5 6 次へ >>

Sequoia Logistica e Tran...

Chemtrade Logistics Income

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約